Inositol guide
General

Inositol (Myo-Inositol)

Myo-inositol is a carbocyclic sugar involved in cellular signaling (inositol phosphates, phosphatidylinositol). It is used as a supplement for PCOS, insulin sensitivity, fertility, and anxiety/panic disorder, with the strongest evidence base in reproductive and metabolic outcomes.

D-chiro-inositol
Inositol hexaphosphate (IP6)
Myo-inositol
Phytic acid
Vitamin B8 (informal)

This guide covers all common forms and variations of inositol (myo-inositol) in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Myo-inositol is a precursor for phosphatidylinositol and inositol phosphates — key molecules in cell membrane signaling. It contributes to second messenger systems including inositol trisphosphate (IP3), which triggers intracellular calcium release and downstream signaling involved in hormone action and neurotransmission.

In metabolic tissues, myo-inositol and D-chiro-inositol act as mediators of insulin signal transduction and glycogen synthesis. Disrupted tissue ratios of these stereoisomers are hypothesized to contribute to insulin resistance in PCOS. In the central nervous system, inositol participates in phosphoinositide cycling that influences serotonergic signaling, which may underlie the effects observed in panic disorder trials.

Myo-inositol molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Endocrine system
Reproductive system
Nervous system
Metabolic regulation

Associated molecules

Myo-inositol
D-chiro-inositol
Phosphatidylinositol (PIP2/PIP3)
Inositol trisphosphate (IP3)

Track it lightly

If you're tracking inositol, log dose, timing, and the most relevant outcome (cycle regularity, fasting glucose, or anxiety frequency) for at least 8–12 weeks to assess benefit.

Trying this? Start tracking it here.

Background

Inositol was first isolated in the 19th century as a component of brain and muscle tissue and was later characterized as a cyclic polyol. Its role in phosphatidylinositol signaling was established in the mid-20th century, and the function of IP3 as a calcium-mobilizing second messenger was described in foundational work by Berridge and colleagues in the 1980s. Clinical interest in supplemental inositol grew in the late 20th century when stereoisomers were investigated for insulin resistance, PCOS, and psychiatric conditions. Research activity has continued, with numerous small RCTs and several systematic reviews now focused on reproductive and metabolic outcomes.

Evidence snapshot

Myo-inositol is well studied in women with PCOS. Multiple randomized controlled trials report that 4 g/day (typically 2 g twice daily) improves ovulation rate, menstrual regularity, and some metabolic parameters including fasting insulin and insulin resistance compared with placebo or baseline. Effect sizes vary and many trials are small, but the direction of evidence is consistent.

Clinical trials have tested high oral doses of inositol (12–18 g/day) for panic disorder and related anxiety endpoints. Benefits for panic attack frequency have been reported in some trials; results are heterogeneous across populations and designs, and the evidence is less consistent than for PCOS.

D-chiro-inositol and fixed-ratio combinations of myo- and D-chiro-inositol have been studied for metabolic and reproductive outcomes in PCOS. Tissue-specific stereoisomer ratios are biologically relevant, and some trial data suggest combined regimens offer advantages over either isomer alone. Short-term use (weeks to months) at doses used in research is generally well tolerated; data beyond 12 months are sparse.

Bioavailability and forms

Myo-inositol is absorbed in the small intestine and distributes broadly, including to the ovaries and brain. Supplemental forms include free myo-inositol powder and fixed-ratio combinations with D-chiro-inositol. Inositol hexaphosphate (IP6, phytic acid) is a phosphorylated plant-derived form with different pharmacokinetics; it is not interchangeable with free myo-inositol for PCOS or anxiety indications. Phosphatidylinositol supplements also exist but are pharmacologically distinct.

Populations studied

Most clinical trials enrolled reproductive-age women with PCOS, including those pursuing natural conception or assisted reproduction. Separate trials assessed metabolic outcomes in insulin resistance and gestational diabetes prevention. Psychiatric trials enrolled adults with panic disorder or obsessive-compulsive disorder. Evidence in men and in older adults is limited; most dosing guidance derives from female PCOS populations.

Long-term safety

Short-term use (weeks to months) of myo-inositol at 2–4 g/day is well tolerated across published trials, with gastrointestinal side effects being the most frequently reported adverse events. Data beyond 12 months are sparse. Doses of ≥12 g/day, used experimentally for psychiatric indications, produce more frequent gastrointestinal complaints. Use in pregnancy at 4 g/day has been studied for gestational diabetes prevention in several trials, but obstetric supervision remains advisable given limited long-term fetal safety data.

Comparisons and combinations

Myo-inositol has been compared with metformin for PCOS-related outcomes in several small trials, with broadly similar effects on ovulation and metabolic markers in some studies, though no consistent superiority over metformin is established. Combined myo-/D-chiro-inositol preparations exploit tissue-specific physiological ratios and are supported by some trial data for combined reproductive and metabolic benefit in PCOS. Direct head-to-head superiority over pharmacological treatments has not been consistently demonstrated across outcomes.

Compound variations

Myo-inositol

Inositol (Myo-Inositol)

The most abundant and most studied supplemental form; the primary choice for PCOS and metabolic studies.

Common use case

PCOS, ovulation support, insulin sensitivity

Dosage note

Standard clinical dose: 2 g twice daily (total 4 g/day).

D-chiro-inositol

Inositol (Myo-Inositol)

A stereoisomer with distinct roles in insulin signaling; studied alone and in combination with myo-inositol for PCOS and metabolic outcomes.

Common use case

Metabolic aspects of insulin resistance; combined regimens for PCOS

Dosage note

Typical single-agent dose in trials: ~600 mg/day; formulations vary.

Myo/D-chiro combination (40:1 ratio)

Inositol (Myo-Inositol)

Fixed-ratio preparations (most commonly 40:1 myo:D-chiro) intended to approximate physiological tissue balance and address both reproductive and metabolic PCOS features.

Common use case

PCOS with both reproductive and metabolic treatment goals

Dosage note

Most studied at a total myo-inositol equivalent of 2–4 g/day with proportional D-chiro-inositol; follow product-specific labeling.

Inositol hexaphosphate (IP6 / phytic acid)

Inositol (Myo-Inositol)

A highly phosphorylated plant-derived form found in seeds and bran. Has different biological properties and is not interchangeable with free myo-inositol for PCOS or anxiety indications.

Common use case

Different research applications; not standard for PCOS or anxiety

Dosage note

Dosing and indications differ substantially from free inositol; consult specific product literature.

Dosage and best practices

Dosage principles

  • PCOS / ovulation: 2 g taken twice daily (total 4 g/day) for at least 2–3 months is the regimen used in the majority of randomized trials.
  • Insulin sensitivity / gestational diabetes prevention: 4 g/day (commonly 2 g twice daily) is the typical research dose; higher doses have been explored but are not standard.
  • Anxiety / panic disorder: Clinical trials used 12–18 g/day in divided doses. These are experimental doses associated with more gastrointestinal adverse effects and should only be used under clinician supervision.

Best practices

  • Take myo-inositol with meals to reduce gastrointestinal discomfort; dividing the total daily dose (e.g., twice daily) is standard practice.
  • In PCOS or fertility contexts, allow 8–12 weeks before evaluating changes in cycle regularity, ovulation, or metabolic markers.
  • Choose preparations with clearly labeled myo-inositol content. Combined myo-/D-chiro-inositol products vary in ratio; a 40:1 myo:D-chiro ratio is the most commonly studied formulation.

Literature and references

Common questions

Is inositol the same as a vitamin?

Inositol is sometimes informally called 'vitamin B8,' but it is not classified as an essential vitamin because the body synthesizes it endogenously. It is considered a conditionally important nutrient in some metabolic contexts.

How long before I see effects for PCOS?

Trials typically detect changes in ovulation rate, cycle regularity, or metabolic markers after 8–12 weeks of continuous supplementation at 4 g/day. Individual responses vary.

Can I take myo-inositol with metformin?

Some clinicians combine them for PCOS. Both affect insulin and glucose metabolism, so blood glucose should be monitored and combined use discussed with a clinician.

Are myo- and D-chiro-inositol interchangeable?

No. They are stereoisomers with distinct tissue distributions and biological roles. Myo-inositol is the most abundant form and is used alone in most trials; D-chiro-inositol and combination formulations target different or overlapping aspects of insulin signaling and reproduction.

Is high-dose inositol safe for anxiety?

Doses of 12–18 g/day used in panic disorder trials are experimental and cause more gastrointestinal side effects than standard doses. Discuss this use with a clinician before attempting high-dose regimens.

Related guides